Volume 9 - Issue 1

Mini Review Biomedical Science and Research Biomedical Science and Research CC by Creative Commons, CC-BY

Influence of Organismal Aging in Mesenchymal Stem Cell Therapy

*Corresponding author: Techung Lee, Department of Biochemistry, University at Buffalo, NY 14203, USA.

Received: June 04, 2020; Published: June 10, 2020

DOI: 10.34297/AJBSR.2020.09.001363


Mesenchymal stem cells (MSCs) from several tissue sources have been investigated in clinical trials for multiple disorders, and mixed results from these trials have been documented [1], indicating that critical variables that can affect the therapeutic outcome remain to be defined. Organismal aging represents a potential impediment to stem cell therapy. Aged tissue often exhibits telomere shortening, increased Wnt signaling, and fibrosis [2,3], and may thus be more refractory to stem cell therapy. Accumulation of extracellular matrix (ECM) components, which invariably causes thickened lamina in aged tissue, can potentially impede the actions of the many growth/trophic factors secreted by the transplanted MSCs. Indeed, the aged heart often exhibits significant functional deteriorations contributed in part by cardiac stem cell senescence and lower capacity for angiogenesis [4]. Impaired HGF/c-Met and Delta/Notch signaling is also prominent in aged tissue [5].

This host tissue deficit remains a major challenge in regenerative medicine because the aging population usually require the therapy. We previously used a hamster (TO2 strain) heart failure model to study cardiac repair mechanisms mediated by MSCs [6]. However, these therapeutic studies were conducted using young animals (~4 months). Since the TO2 hamster heart is known to exhibit an early aging phenotype due to progressive loss of cardiomyocytes and functional decline, it is important to determine whether the aging heart of older TO2 hamster may be able to achieve functional improvement in response to MSC therapy. Echocardiography performed 1 month after MSC injection shows that both the saline (HBSS) - and MSC-treated old TO2 hamsters exhibited a similar decline in function as indicated by indistinguishable fractional shortening (FS) and left ventricular end-diastolic dimension (LVDd) between the two groups (Figure 1).

Biomedical Science &, Research

Figure 1: MSCs failed to improve cardiac function in old cardiomyopathic hamster. Ten-month-old F1B (normal) and TO2 hamsters were used for the study. TO2 hamsters received injections of Hanks Balanced Salt Solution (HBSS) or MSCs (n=5 per group). Echo measurements of %FS and LVDd were performed before injection and 1 month after injection. *p<0.05 vs. F1B; #p<0.05 vs. pre-injection.

Thus, although MSC therapy is effective in treating younger TO2 hamsters, it is ineffective in treating the older cardiomyopathic hamsters. Advanced age typically exhibits more prevalent adverse events in humans. Although the human heart has been known to harbor a significant number of resident stem cells possessing limited regeneration capacity, age-related ECM remodeling and stem cell senescence can lead to declining cardiomyocyte populations and myocardial dysfunction [7, 8]. Similar to our finding here, the cardiovascular beneficial effects of G-CSF and ischemic preconditioning were found to be impaired by aging [9,10]. Since the failing hamster heart exhibits abnormally active Wnt signalingmediated fibrosis, excessive fibrosis in the 10-month TO2 heart may profoundly interfere with the growth factor signaling cascade mediated by the administered MSCs. The finding highlights the progressive nature of the fibrogenic process in the cardiomyopathic heart, which can interfere with the regenerative therapy. Thus, host tissue aging/fibrosis represents a major consideration in the design of MSC therapy.


Sign up for Newsletter

Sign up for our newsletter to receive the latest updates. We respect your privacy and will never share your email address with anyone else.